Molecular characterization of chronic liver disease dynamics: From liver fibrosis to acute-on-chronic liver failure
Isabel Graupera,
Laura Isus,
Mar Coll,
Elisa Pose,
Alba Díaz,
Julia Vallverdú,
Teresa Rubio-Tomás,
Celia Martínez-Sánchez,
Patricia Huelin,
Marta Llopis,
Cristina Solé,
Elsa Solà,
Constantino Fondevila,
Juan José Lozano,
Pau Sancho-Bru,
Pere Ginès,
Patrick Aloy
Affiliations
Isabel Graupera
Liver Unit, Hospital Clínic, Barcelona, Catalonia, Spain; Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain; Medicine department, Faculty of Medicine, University of Barcelona, Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Catalonia, Spain; Corresponding authors. Addresses: Liver Unit, Hospital Clinic Barcelona, Villarroel, 170, 08036 Barcelona, Spain
Laura Isus
Institute for Research in Biomedicine (IRB Barcelona) and The Barcelona Institute of Science and Technology. Barcelona, Catalonia, Spain
Mar Coll
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain; Medicine department, Faculty of Medicine, University of Barcelona, Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Catalonia, Spain; Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Rosselló, 149-153, 08036 Barcelona, Spain. Tel. +34 932275400 Ext. 4535.
Elisa Pose
Liver Unit, Hospital Clínic, Barcelona, Catalonia, Spain; Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Catalonia, Spain
Alba Díaz
Pathology Service, Hospital Clinic-IDIBAPS, Barcelona, Spain; Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Julia Vallverdú
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain
Teresa Rubio-Tomás
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain
Celia Martínez-Sánchez
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain
Patricia Huelin
Liver Unit, Hospital Clínic, Barcelona, Catalonia, Spain
Marta Llopis
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain
Cristina Solé
Liver Unit, Hospital Clínic, Barcelona, Catalonia, Spain
Elsa Solà
Liver Unit, Hospital Clínic, Barcelona, Catalonia, Spain
Constantino Fondevila
Dept. of General and Digestive Surgery, Hospital Universitario La Paz, IdiPAZ, CIBERehd, Madrid, España
Juan José Lozano
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Catalonia, Spain
Pau Sancho-Bru
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain; Medicine department, Faculty of Medicine, University of Barcelona, Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Catalonia, Spain
Pere Ginès
Liver Unit, Hospital Clínic, Barcelona, Catalonia, Spain; Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain; Medicine department, Faculty of Medicine, University of Barcelona, Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Catalonia, Spain
Patrick Aloy
Institute for Research in Biomedicine (IRB Barcelona) and The Barcelona Institute of Science and Technology. Barcelona, Catalonia, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain
Background & Aims: The molecular mechanisms driving the progression from early-chronic liver disease (CLD) to cirrhosis and, finally, acute-on-chronic liver failure (ACLF) are largely unknown. Our aim was to develop a protein network-based approach to investigate molecular pathways driving progression from early-CLD to ACLF. Methods: Transcriptome analysis was performed on liver biopsies from patients at different liver disease stages, including fibrosis, compensated cirrhosis, decompensated cirrhosis and ACLF, and control healthy livers. We created 9 liver-specific disease-related protein-protein interaction networks capturing key pathophysiological processes potentially related to CLD. We used these networks as a framework and performed gene set-enrichment analysis (GSEA) to identify dynamic gene profiles of disease progression. Results: Principal component analyses revealed that samples clustered according to the disease stage. GSEA of the defined processes showed an upregulation of inflammation, fibrosis and apoptosis networks throughout disease progression. Interestingly, we did not find significant gene expression differences between compensated and decompensated cirrhosis, while ACLF showed acute expression changes in all the defined liver disease-related networks. The analyses of disease progression patterns identified ascending and descending expression profiles associated with ACLF onset. Functional analyses showed that ascending profiles were associated with inflammation, fibrosis, apoptosis, senescence and carcinogenesis networks, while descending profiles were mainly related to oxidative stress and genetic factors. We confirmed by qPCR the upregulation of genes of the ascending profile and validated our findings in an independent patient cohort. Conclusion: ACLF is characterized by a specific hepatic gene expression pattern related to inflammation, fibrosis, apoptosis, senescence and carcinogenesis. Moreover, the observed profile is significantly different from that of compensated and decompensated cirrhosis, supporting the hypothesis that ACLF should be considered a distinct entity. Lay summary: By using transjugular biopsies obtained from patients at different stages of chronic liver disease, we unveil the molecular pathogenic mechanisms implicated in the progression of chronic liver disease to cirrhosis and acute-on-chronic liver failure. The most relevant finding in this study is that patients with acute-on-chronic liver failure present a specific hepatic gene expression pattern distinct from that of patients at earlier disease stages. This gene expression pattern is mostly related to inflammation, fibrosis, angiogenesis, and senescence and apoptosis pathways in the liver.